ORIC Pharmaceuticals, Inc. (ORIC)

NASDAQ: ORIC · Real-Time Price · USD

9.58

-0.35 (-3.52%)

Aug 15, 2025, 10:56 AM - Market open

ORIC Pharmaceuticals Employees

ORIC Pharmaceuticals had 115 employees as of December 31, 2024. The number of employees increased by 15 or 15.00% compared to the previous year.

Employees

115

Change (1Y)

15

Growth (1Y)

15.00%

Revenue / Employee

n/a

Profits / Employee

-$1,193,470

Market Cap

816.45M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	115	15	15.00%
Dec 31, 2023	100	14	16.28%
Dec 31, 2022	86	8	10.26%
Dec 31, 2021	78	17	27.87%
Dec 31, 2020	61	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

ORIC News

2 days ago - ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates - GlobeNewsWire
13 days ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
2 months ago - ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital - Benzinga
2 months ago - ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing - GlobeNewsWire
2 months ago - ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC - GlobeNewsWire
2 months ago - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
2 months ago - ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC - GlobeNewsWire
3 months ago - ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - GlobeNewsWire